@FierceBiotech: GeNO, uniQure look to leap through biotech IPO window in Q4 rush. More | Follow @FierceBiotech
@JohnCFierce: True, first wave of cancer vaccines has been a disappointment. Good reason for skepticism as well--but that's almost always the case. | Follow @JohnCFierce
@DamianFierce: Updated: Roche taps immatics in immunotherapy cancer R&D deal worth up to $1B. More | Follow @DamianFierce
@EmilyMFierce: Yale study: Left-handed people have higher rates of schizophrenia, other psychotic disorders. News | Follow @EmilyMFierce
> Novelos Therapeutics is shuttering an executive office in Newton, MA, and putting its executive team in its existing facilities in Madison, WI. In a reorganization, the company, which ran into serious trouble back in 2010 following the failure of a lung cancer drug study, also named Simon Pedder as acting CEO and reduced the size of the board from 9 members to 5. Release
> Houston-based ApoCell, which has been working on tumor cell isolation tech, is setting up a lab in Leipzig, Germany, to collaborate more closely with the Fraunhofer Institute for Cell Therapy and Immunology. Story
> InnoPharm closed on a $20 million term loan facility provided by Athyrium Capital Management. Release
> San Diego-based Apricus Biosciences signed an exclusive license agreement with Laboratoires Majorelle to market Vitaros, its topical treatment for erectile dysfunction, in France, Monaco and certain African countries. Release
@FierceMedDev: Syneron fattens revenue with slim-down, North American focus. More | Follow @FierceMedDev
@MarkHFierce: The latest weekly edition of FierceDiagnostics is ready for viewing. Check it out, and spread the word. Issue | Follow @MarkHFierce
@MichaelGFierce: Brain tumors succumb to drugs delivered via bone scaffold. News | Follow @MichaelGFierce
> Boston Scientific sets FDA date for closely watched Watchman. Article
> FDA slaps 'deadly' tag on Atossa's cancer Dx recall. Piece
> Syneron fattens revenue with slim-down, North American focus. More
> Myriad's melanoma Dx launch continues aggressive test rollout. Item
Pharma News
@FiercePharma: Tuesday's top news: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Story | Follow @FiercePharma
@EricPFierce: Actavis takes aim at North Carolina plant, 310 jobs, as it looks to cut costs. More | Follow @EricPFierce
@CarlyHFierce: CFR chief angles for meeting with Adcock Ingram after top investor nixes $1.3B deal. Story | Follow @CarlyHFierce
> 2013's story: Fewer drug approvals, better selling drugs. Article
> AstraZeneca wins, Merck and AbbVie lose with new statin-use guidelines. Story
> Is Endo on the verge of a Valeant-type acquisition binge? Article
> Sanofi tries label gambit to hold off Nasacort copies. More
Drug Delivery News
> MedImmune taps Unilife for wearable biologic injectable tech. Report
> DNA-delivering patch spurs bone growth. Story
> Study: Once-toxic peptide may deliver large molecules. Article
> Sustained-release glaucoma treatment nets $25M for Liquidia's Envisia. More
> Brain tumors succumb to drugs delivered via bone scaffold. Report
> Carbon nanotubes sneak drugs past gatekeeper proteins. Item
Diagnostics News
> Response Genetics sees disappointing Q3 as Dx revenue declines. Story
> VolitionRx, heartened by early data, shifts to multiple colorectal cancer Dx studies. Article
> Ex-Sequenom CEO seeks compensation in wake of scandal-related firing. More
> Oxford Immunotec's Dx milestones could supercharge IPO. Report
> Myriad gears up for melanoma test rollout. Story
> Myriad's signature BRCA test continues to generate lion's share of revenue. Item
Biomarkers News
> Study: Left-handed people have higher rates of schizophrenia, other psychotic disorders. Story
> J&J, nonprofits fund new research into links between Down syndrome, Alzheimer's. More
> Protein in damaged tissue could be biomarker for muscular dystrophy. Article
> Biomarker could predict preeclampsia in pregnant women. Report
> U.K. crew eyes biomarker as flag for atrial fibrillation complications. Story
> Researchers flag protein biomarker for aggressive oral cancer. Item